

PhenoTox: Hunting the missing heritability of early-onset fluoropyrimidine-related toxicity in cancer patients: an observational multi-center study

Markus Joerger

In cancer patients receiving fluoropyrimidine-based chemo-therapy, there is extensive inter-individual variability in plasma drug concentrations and the severity of chemo-therapy-related toxicity. A strong association has been shown for plasma concentrations and drug-related toxicity as well as clinical outcome in 5-fluorouracil treated cancer patients. In spite of the identification of some genetic risk factors that contribute to this inter-individual variability, a majority of toxicity occurrences remain unexplained. Currently, variability in drug exposure related to BSA-based dosing hampers the identification of genetic factors contributing to individual FP toxicity risk and the quantification of their clinical relevance. Thus, the power of association studies can be improved by accounting for differences in individual drug exposure.

type of project	clinical studies
status	ongoing - recruiting phase
start of project	2016
end of project	2020
responsible person	PD Dr. med. Markus Jörger